Skip to main content
ENSC
NASDAQ Life Sciences

Ensysce Sets Dec 23 Vote on 1,793% Series C Conversion, 1-for-10 to 1-for-30 Reverse Split

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.431
Mkt Cap
$8.191M
52W Low
$0.23
52W High
$2.23
52W Position info
88% above low
Off High info
81% below high
Rel. Volume
Market data snapshot near publication time

ENSC sits 88% above its 52-week low of $0.23.

Summary

Ensysce's preliminary proxy sets a December 23, 2026 vote on converting Series C preferred into about 358.3 million shares (roughly 1,793% of current shares outstanding), alongside a 1-for-10 to 1-for-30 reverse split and an increase in authorized shares to 500 million.


Key Events · Corporate Governance and Compliance · ENSC

  • Vote Set on 358.3M-Share Conversion

    Proposal 1 seeks approval under Nasdaq Rules 5635(a) and 5635(b) to issue the common stock underlying Series C preferred; conversion would produce 377,748,794 shares outstanding versus 19,456,794 today, with the new shares equal to about 95% of the post-deal count.

  • Reverse Split of 1-for-10 to 1-for-30

    The Board would pick a ratio in that range before February 5, 2027, targeting a post-split price of roughly $7.00-$11.00 to meet Nasdaq's $4.00 initial listing bid requirement triggered by the change-of-control ruling.

  • Authorized Shares Would Double

    Proposal 3 would raise authorized common stock from 250,000,000 to 500,000,000 shares; the company says current authorization is insufficient if all 433,907,000 Series C underlying shares convert.

  • Delisting Risk If Conversion Fails

    The filing states that without approval the company cannot issue the conversion shares without facing Nasdaq delisting, and it must call a meeting every six months until approval is obtained.


Analysis · ENSC · Life Sciences

Shareholders are being asked to authorize conversion of Series C preferred into roughly 358.3 million common shares — about 1,793% of the 19.5 million shares outstanding — which would hand control to former Cy Biopharma holders and PIPE investors. In practice, approval is not optional: Nasdaq has ruled the Cy deal a change of control, so the company must clear initial listing requirements, including a $4.00 minimum bid price, before conversion. That is why the reverse split (1-for-10 to 1-for-30, targeting roughly $7-$11 per share) and the doubling of authorized shares to 500 million are bundled in. Should Proposal 1 fail, the company says it faces delisting and must keep re-soliciting every six months. The vote is the last gate between the August merger and a fully converted, majority-new-owner capital structure.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ENSC was trading at $0.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $0.23 to $2.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ENSC - Latest Insights

ENSC
Nov 12, 2026, 11:18 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.380
Real-time Price: $0.416915 info
Change: +$0.036915 (+10%) info
Market Cap: $8.141M info
ENSC
Nov 12, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.3871
Real-time Price: $0.416915 info
Change: +$0.029815 (+8%) info
Market Cap: $8.141M info
ENSC
Nov 12, 2026, 4:17 PM EST
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.3871
Real-time Price: $0.416915 info
Change: +$0.029815 (+8%) info
Market Cap: $8.141M info
ENSC
Nov 12, 2026, 4:15 PM EST
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $0.3871
Real-time Price: $0.416915 info
Change: +$0.029815 (+8%) info
Market Cap: $8.141M info
ENSC
Nov 04, 2026, 12:46 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.3719
Real-time Price: $0.416915 info
Change: +$0.045015 (+12%) info
Market Cap: $8.141M info